Methods for preventing or treating excess weight using oxyntomodulin

Abstract

Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . A method for the prevention or treatment of excess weight in a mammal, the method comprising administering a composition comprising oxyntomodulin to a mammal. 
     
     
         7 . The method of  claim 6 , wherein the excess weight is obesity. 
     
     
         8 . A method for cosmetic weight loss in a mammal, the method comprising administering a composition comprising oxyntomodulin to a mammal. 
     
     
         9 . The method of  claim 6 , wherein the composition comprises oxyntomodulin and a pharmaceutically acceptable excipient or carrier. 
     
     
         10 . The method of  claim 6 , wherein the weight loss is a result of reduced food intake. 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 6 , wherein the mammal is a human. 
     
     
         19 . The method of  claim 6 , wherein the composition is in liquid, solid or semi-solid form. 
     
     
         20 . The method of  claim 6 , wherein said oxyntomodulin is administered to said mammal by oral, parenteral, intraperitoneal, mucosal, rectal, subcutaneous or transdermal administration. 
     
     
         21 . The method of  claim 20 , wherein said oxyntomodulin is administered to said mammal by inhalation or by buccal, sublingual or nasal administration. 
     
     
         22 . The method of  claim 6 , wherein said oxyntomodulin is administered to said mammal in the presence of a metal. 
     
     
         23 . The method of  claim 6 , wherein said oxyntomodulin is formulated as a salt or is in a conjugated form. 
     
     
         24 . The method of  claim 6 , wherein the histidine residue at position 1 of said oxyntomodulin is replaced by another aromatic amino acid carrying a positive charge, or an isomeric form of said histidine residue. 
     
     
         25 . The method of  claim 6 , wherein one or more of up to 16 amino acid residues other than histidine at position 1 of said oxyntomodulin are independently replaced by another amino acid residue. 
     
     
         26 . The method of  claim 6 , wherein 1, 2, 3, 4, or 5 amino acid residues of said oxyntomodulin are removed from the oxyntomodulin sequence with the exception of histidine at position 1. 
     
     
         27 . The method of  claim 6 , wherein the C terminus of said oxyntomodulin is modified by the addition of further amino acid residues. 
     
     
         28 . The method of  claim 6 , wherein said oxyntomodulin is a human oxyntomodulin. 
     
     
         29 . The method of  claim 6 , wherein said oxyntomodulin is conjugated to a lipid or polyethylene glycol. 
     
     
         30 . The method of  claim 6 , wherein said oxyntomodulin is acetylated or amidated. 
     
     
         31 . The method of  claim 6 , wherein the metal is calcium, iron, magnesium, manganese, or zinc. 
     
     
         32 . The method of  claim 6 , wherein the histidine residue at position 1 of said oxyntomodulin is replaced by another aromatic amino acid carrying a positive charge, or an isomeric form of the histidine residue, and wherein one or more of up to 16 of the amino acid residues other than histidine at position 1 are independently replaced by another amino acid residue.